Han S, Huang W, Liu Y, Pan S, Feng Z, Li S
1First College of Clinical Medicine, Guangxi Medical University, Nanning, China.
Perfusion. 2013 Nov;28(6):474-83. doi: 10.1177/0267659113492837. Epub 2013 Jun 19.
Blood cardioplegia in cardiac surgery contains leukocytes, which causes the inflammatory reaction and promotes myocardial reperfusion injury. The removal of leukocytes from the cardioplegia line, using specialized filters, has been proposed as one of the effective methods in attenuating the inflammatory response. We performed a two-level search to identify randomized, controlled trials concerning the effects of leukocyte-depleted blood cardioplegia on myocardial reperfusion injury. Sixteen studies, comprising 738 patients, met the selection criteria. There are significant reductions in creatinine kinase isoenzyme MB (CK-MB) during 4-8h postoperatively (SMD - 0.577; 95% CI -0.795 to -0.358; p=0.000), CK-MB peak (SMD - 0.713; 95% CI -1.027 to -0.400; p=0.000), troponin in the period of 4-8h postoperatively (SMD - 0.502; 95% CI -0.935 to -0.069; p=0.023), troponin peak (SMD - 0.826; 95% CI -1.373 to -0.279; p=0.003) and inotropic support (RR, 0.500; 95% CI 0.269 to 0.931; p=0.029). Leukocyte-depleted blood cardioplegia may reduce myocardial reperfusion injury in the early postoperative period, but there has been no evidence to support the clinically significant difference. Larger and more precise randomized control trials are needed to further elucidate the cardioprotective effects of cardioplegia leukofiltration.
心脏手术中的血液停搏液含有白细胞,可引发炎症反应并促进心肌再灌注损伤。使用专门的过滤器从停搏液管路中去除白细胞,已被提议作为减轻炎症反应的有效方法之一。我们进行了两级检索,以确定关于去白细胞血液停搏液对心肌再灌注损伤影响的随机对照试验。16项研究,共738例患者,符合入选标准。术后4 - 8小时肌酸激酶同工酶MB(CK - MB)(标准化均数差 - 0.577;95%可信区间 - 0.795至 - 0.358;p = 0.000)、CK - MB峰值(标准化均数差 - 0.713;95%可信区间 - 1.027至 - 0.400;p = 0.000)、术后4 - 8小时肌钙蛋白(标准化均数差 - 0.502;95%可信区间 - 0.935至 - 0.069;p = 0.023)、肌钙蛋白峰值(标准化均数差 - 0.826;95%可信区间 - 1.373至 - 0.279;p = 0.003)及血管活性药物支持(相对危险度,0.500;95%可信区间0.269至0.931;p = 0.029)均显著降低。去白细胞血液停搏液可能会减少术后早期的心肌再灌注损伤,但尚无证据支持其具有临床显著差异。需要更大规模、更精确的随机对照试验来进一步阐明停搏液白细胞过滤的心脏保护作用。